Background: Gene therapy is expected to play a major role in medical treatment in the future. Several different methods for DNA transfection exist. We evaluated the efficacy and effects of transfection by acoustic energy in a standardized prostate cancer model. Methods: Subcutaneous implantation of Dunning tumors was followed by injection of pEGFP-DNA plasmid. Tumors were treated by acoustic energy with different parameter settings and the transfection rate was assessed by FACScan. Results: Standardized experimental conditions resulted in minor intragroup deviations. Intratumoral injection resulted in a transfection rate of 0.3% (control group). The statistically significant increase of 4.6% in cell transfection rate was gained by applying acoustic energy. Conclusions: DNA transfection of solid tumors can be mediated by the application of acoustic energy. Achieved transfection rates are encouraging and imply therapeutical levels. Prodrug activation or suicide gene therapy are possible fields of investigation in the treatment of prostate cancer.
Introduction
Development of recombinant DNA technologies has led to characterization of specific, disease-related genes. These genes may be regarded as new targets in a therapeutic disease approach. 1 Therefore, gene transfection-the intracellular delivery of DNA-is one of the most promising techniques in the treatment of oncological diseases. Existing methods of transfection such as viral vectors, 2 electroporation as a physical strategy 3 or direct injection of DNA 4 display individual advantages and disadvantages. Immunological problems, dissatisfactory transfection rates or the inability to transfect unaccessible tissue within the body, are common and well-known. 1 Highly energetic acoustic energy is known to increase the permeability of cell membranes over a short period of time. [5] [6] [7] The cellular uptake of large molecules can be achieved with the use of this mechanism. 8 Advantages of acoustic energy are its possible application in difficultly accessible tissue such as the prostate gland and the low number of side effects. 7 In previous studies we demonstrated that acoustic energy can mediate gene transfection at a high level of efficiency. By acoustic energy, transfection rates up to 24.9% were achieved in a standardized in vitro model in Dunning R-3327 (MatLu) cells-a rat prostate carcinoma cell line. 9 However, only little knowledge exists on the possible transfection and transfection rates of prostate adenocarinoma cells evoked by acoustic energy in an in vivo environment. Our aim was to assess the efficacy and side effects of acoustic energy in the gene transfection of prostate cancer cells in vivo. The establishment of a standardized and reproducible transfection model as well as the quantification of transfection rates with the underlying factors of influence was of special interest. Acoustic energy was applied by a electromagnetic shock wave generator. The Copenhagen rat Dunning R-3327 prostate cancer model was used to assess transfected cells by protein expression of reporter gene EGFP-N1 in FACS analysis.
Materials and methods

Cell culture and animal model
The Dunning R-3327 Copenhagen rat model was used for transfection. Briefly, MatLu prostate cancer cells (No. 94102735, European Collection of Cell Cultures, Salisbury, UK) were cultured at 371C, 5% CO 2 and 100% air humidity in 75 cm 3 Falcon cell culture flasks (Becton Dickinson). MatLu cells were maintained in RPMI 1640 medium (Gibco BRL, Life Technologies, Rockville, USA) supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 4 mM l-glutamine (Gibco BRL) and 250 nM dexamethasone (Sigma, St Louis, USA); RT-112 and COS-7: DMEM media (Gibco BRL), 10% FBS and 4 mM l-glutamine. Subcultivation was carried out at 75% confluency using 3 ml trypsin EDTA (Gibco BRL). All steps were carried out under sterile conditions.
A cell pellet of two subconfluent flasks was implanted subcutaneously into the upper limb of Copenhagen rats of 4-6 months age and 250-350 g b.w. (Harlan SpragueDawley, Harlan-Winkelmann GmbH, Borcken, Germany) by open surgery under general anesthesia (ketamine/ xylazine). After 14 days, the tumor was excised and served as donator for rats in the experimental group. Fresh pieces of tumor (1-2 mm 2 ) were implanted as described above.
After implantation, tumors were allowed to grow for 10-14 days with a resulting tumor volume of approximately 1.0-1.8 cm 3 . The tumor volume was calculated by the formula of length Â width Â height Â 0.5. Overall, 18 animals were used (12 animals in the therapeutic group and six as controls).
At the end of the trials, the animals were killed by CO 2 intoxication. The animal trials were conducted in accordance with the guidelines for laboratory animals issued by the German government and were approved by the local municipal government in Karlsruhe (application No.: 35-9185.81/124/00).
Reporter plasmids
pEGFP-N1, a mutation of reporter gene GFP, was used for transfection rate analysis (Clontech, Palo Alto, CA, USA). This red-shift variant displays a maximum of excitation at 490 nm with an emission maximum of 507 nm. 10 The plasmid was kindly provided by Professor Hafner (University of Applied Sciences, Mannheim, Germany). The plasmid has been cloned into E. coli stem DH5a (high copy number 500) as a glycine stock. For preparation, DNA was purified by a standard method (Qiafilter-Plasmid-Gigakit, Qiagen, CA, USA) and adjusted to 0.5 mg/ml in Tris EDTA buffer (Sigma).
Transfection by acoustic energy
For in vivo transfection, the experimental electromagnetic shock wave generator Modulith SLK (Storz Medical, Kreuzlingen, Switzerland) was used. Rats were placed sideways under the generator-integrated diagnostic ultrasound (3.5 Hz) with maximum contact area of the coupling device and skin surface. The therapeutic focus was directed to the center of the tumor. The subcutaneous tumor was punctured on one side with a canula and injection of plasmid solution (0.5 mg/ml) over 60 s followed. The volume of injected plasmid solution was adapted to 10% of estimated individual tumor volume. With the canula in place, air (volume equivalent to injected plasmid solution) was slowly injected into the center of the tumor in order to increase transfection by cavitation effects.
Shock waves were delivered at an energy level of 0.5 mJ/mm 2 and a frequency of 2 Hz. Two therapeutic groups were treated with either 1000 (group 1: eight animals) or 2000 impulses (group 2: eight animals). The injection of plasmid solution and air as well as the shock wave treatment was performed under general anesthesia.
The experimental setup is summarized in Figure 1 .
Tumor preparation and FACScan
After treatment, tumors were surgically resected in toto.
The specimens were washed in 50 ml of above-mentioned media with additional gentamycin (50 mg/ml, Sigma). The tumor was dissected into approximately 2 mm 3 portions under sterile conditions and incubated in 20-40 ml of enzymes (collagenase 0.14% and hyaluronidase 0.3% in NaCl, Sigma) for 45 min at 371C under moderate stirring to acquire a single-cell suspension. The suspension was filtered once through a metal filter (pore size 250 mm, Fisher Scientific, Schwerte, Germany) and centrifuged at 250 g for 5 min. After resuspension in cell culture media and centrifugation twice, cells were cultivated at 10 7 cells in 75 cm 3 flasks with 10-20 ml of cell culture media (add gentamycin, 50 mg/ml). With one change of media, FACScan of reporter gene expression in transfected cells was performed after 24 h of incubation. A minimum of 10 000 cells per sample was analyzed.
The FITC filter set was used for analysis of EGFPExpression with FACScalibur Cytometry (BD Immunocyometry San Jose, CA, USA) at 488 nm. Data were processed by the FACScan software Cell Quest.
Control group
Six animals served as controls. No acoustic energy was applied to the controls, but they were injected with Figure 1 Experimental setup of a standardized in vivo transfection model using acoustic energy. Subcutaneously growing Dunning R-3327 (MatLu) tumors are injected with DNA plasmid/air solution, followed by treatment with electromagnetic shock waves. Explanted tumors are recultivated in cell culture and the transfection rate is assessed by FACScan for reporter gene expression.
In vivo transfection of prostate cancer MS Michel et al plasmid solution and air as described above. Tumors were explanted 10 min after injection and processed as described above.
Statistical analysis
Diverging statistics between the control group and treated animals were determined using the Wilcoxon score (rank sum) test. One-sided Po0.05 was considered to be significant (t approximation). Statistical analyses including calculation of mean value (MV) and standard deviation (s.d.) was performed by SAS System (Release 8.02; SAS Insitute Inc., Cary, NC, USA).
Results
General observations
The implantation of tumors was carried out without any problems. All animals survived the surgical procedure. Tumor growth was achieved in all cases except one where the implanted tumor did not grow. Exact focusing of the subcutaneous tumor by diagnostic ultrasound and injection of plasmid or air was possible in all cases, although time consuming in several cases. An example of subcutaneously growing Dunning R-3327 prostate cancer tumor during plasmid injection is shown in Figure 2 .
Transfection by electromagnetic shock waves
During treatment with acoustic energy, impulse-dependent hemorrhage was observed in the animals on the overlaying skin and in areas within the tumor. A greater extent of hemorrhage was seen in experimental group 2 that was treated with 2000 impulses of acoustic energy in comparison to group 1 treated with 1000 impulses.
Cell survival rate was assessed by cell counting after staining with trypan blue (GibcoBRL) and the transfection rate was measured by FACScan analysis. A representative FACScan histogram is shown in Figure 3 . The cell survival rate of tumor cells after shock wave treatment ranged from 40 to 60%.
Tumors in the negative control group revealed a transfection rate between 0.1 and 0.5%. In comparison with the control group, a statistically significant enhanced transfection rate was observed in all the treated animals. The transfection rate increased to a mean value of 2.670.94% (group 1-1000 impulses; Po0.01) and 4.771.43% (group 2-2000 impulses; Po0.01) in direct comparison to the control group (Figure 4) . The number of impulses delivered significantly influenced the transfection rate: the tumors in group 2 displayed a higher percentage of transfected cells compared to the tumors in group 1 (P ¼ 0.01).
Discussion
Prostate cancer appears as a heterogenous tumor with multiple genes involved in its carcinogenesis, either as enhanced tumor promotors or as downregulated tumor 14 Adenoviral vectors with the ability to transfect dormant cells are known to have a high immunogenic potential, which makes repeated application impossible. 12 A physical method of cellular DNA transferral is the application of acoustic energy. Previous studies demonstrated transfection rates in HeLa cells (derived from human cervical adenocarcinoma) ranging from 0.1 to 0.5%, which depended on the number of impulses. A positive effect of rising DNA concentration was observed. 7 In previous studies, we used a new experimental electromagnetic shock wave generator with optimal parameter settings (200 mg/ml plasmid DNA, energy density: 0.5 mJ/mm 2 , frequency: 2 Hz) and thus demonstrated DNA transfection rates of up to 24.9% in an in vitro experimental setup. 9 In preexperiments, pEGFP transfection was stable at 16-24 h after shockwave treatment in different cell lines.
Using the same principles in our Dunning rat prostate cancer in vivo model, we achieved transfection rates of up to 8% with optimal parameter settings of 0.5 mJ/mm 2 energy density and a frequency of 2 Hz. The transfection rate was impulse-dependent and the number of transfected cells increased from 2.6 to 4.6% (mean values). Therefore, we were able to demonstrate the possibility of in vivo gene transfection in a prostatic carcinoma model.
Conclusions
The results obtained by us in our investigations on prostate cancer cell transfection in vivo by the use of acoustic energy will allow further investigations into promising new therapeutic transfection strategies. Transfection with enzymes that transform chemotherapeutics from a nontoxic to a toxic form is likely one of the new therapeutic strategies. 'By-stander' effects, such as the damage of nontransfected cells located in close proximity to transfected cells, may lead to a satisfactory therapeutic effect of 10% transfected cells. 15 
